Therapsil CEO Spencer Hawkswell Speaks To Health Canada’s Intent To Deny Section 56 Exemptions To Healthcare… Feb 9, 2022
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of… Feb 9, 2022
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada Feb 8, 2022
